cancer centresoncologyneuroimmunological disordersB-cell mediated autoimmune diseaserelapsed or refractory haematological malignanciesChimeric antigen receptor (CAR)-T cell therapiesCAR-T cell therapies
…er and more focal toxicities. As CAR-T cell therapies move from cancer centres into the care of patients with refractory neuroimmunological di…